The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Official Title: An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Study ID: NCT04507503
Brief Summary: The objective of the study is to provide access to TAS-120 to patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements.
Detailed Description: This is an open-label study to provide expanded access to TAS-120 prior to its commercial availability for patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements who have failed standard therapy or who are unable to tolerate standard therapy.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Banner MD Anderson, Gilbert, Arizona, United States
University of California, San Francisco (UCSF), San Francisco, California, United States
UCLA Division of Hematology-Oncology, Santa Monica, California, United States
Mount Sinai Center of Florida, Miami Beach, Florida, United States
Advent Health Orlando, Orlando, Florida, United States
University of Chicago, Chicago, Illinois, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Kansas Cancer Center, Lee's Summit, Missouri, United States
Duke University Medical Center, Durham, North Carolina, United States
Providence Portland Medical Center, Portland, Oregon, United States
MD Anderson, Houston, Texas, United States
Utah Cancer Specialists, Salt Lake City, Utah, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Aurora Cancer care, Grafton, Wisconsin, United States